Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:30 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17795

Shown on this page

Current sort

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 99 Years
Enrollment: 12,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 140
States / cities: Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more

Conditions: Obesity
Interventions: survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 153
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more

Conditions: Nonsuicidal Self Injury, Suicidal Ideation, Depression, Anxiety
Interventions: Self-guided digital intervention for NSSI, Digital intervention for NSSI with coaching, Active control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Borderline Personality Disorder, Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Focal Seizures
Interventions: CBD-OS; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more

Conditions: Solid Tumors, Hematologic Malignancies
Interventions: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 65
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more

Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions: Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 288
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more

Conditions: Candida Auris Infection, Colonization, Asymptomatic
Interventions: Povidone Iodine Topical; Drug
Lead sponsor: Mary K Hayden; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Chicago, Illinois • Hinsdale, Illinois

Conditions: Left Atrial Appendage Exclusion
Interventions: Penditure™ Left Atrial Appendage (LAA) Exclusion System; Device
Lead sponsor: Medtronic Cardiac Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 15
States / cities: Atlanta, Georgia • Chicago, Illinois • Carmel, Indiana + 12 more

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more

Conditions: RSV Respiratory Syncytial Virus
Interventions: AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Clinical trials in Chicago, Illinois

Filter and sort this location

Institutions in Chicago

Live official records

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Digital Mental Health Intervention for Nonsuicidal Self-Injury in Young Adults

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Nasal Antisepsis for C. Auris Prevention

CLIP-IT Post-Market Study

Pancreatic Cancer Early Detection Consortium

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)